Abstract
Genital herpes is a chronic viral infection in the genital area caused by the herpes simplex virus type 1 or type 2 (HSV-1, HSV-2). It is one of the several reasons of the genital ulcer disease (GUD) with recurrent blisters and painful erosions in the same area of the skin. Most cases of recurrent genital herpes are caused by HSV-2. Atypical clinical lesions and unclear manifestations should be confirmed by laboratory diagnosis using the PCR as the gold standard method for the diagnosis and identification of HSV-1 or HSV-2. The appropriate treatment with nucleoside analogues is recommended for first episodes as well as for painful recurrent genital herpes and should start as soon as possible and with high dosages. It offers clinical benefit for symptomatic individuals, partners, and neonates and can reduce the number of herpetic recurrences and asymptomatic viral shedding.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121:847–54.
Brown ZA, Selke S, Zeh J, et al. Acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509–15.
Bryson YJ, Dillon M, Bernstein DI, Radolf J, Zakowsi P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis. 1993;167:942–6.
Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427–39.
Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med. 2009;361:1376–85.
Corey L, Wald A, Patel R, et al. Once daily Valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11–20.
Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? Sex Transm Infect. 2002;78:346–8.
Coyle PV, O’Neill HJ, Wyatt DE, McCaughey C, Quash S, McBride MQ. Emergence of herpes simplex type 1 as the main cause of recurrent genital ulcerative disease in women in Northern Ireland. J Clin Virol. 2003;27:22–9.
Crumpacker CS, Schnipper LE, Marlowe ST, Kowalsky PN, Hershey BJ, Levin MJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982;306:343–6.
Dillon SM, Cummings SM, Rajagopalan S, Mc Cormack WC. Prospective analysis of genital ulcer disease in Brooklyn, New York. Clin Infect Dis. 1997;24:945–50.
Engel JP, Englund JA, Fietcher CV, et al. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA. 1990;236:1662–4.
Five KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS, the Acyclovir Study Group. Recurrence and resistance pattern of herpes simplex virus following cessation of ≥ 6 years of chronic suppression with acyclovir. J Infect Dis. 1994;169:1338–41.
Fleming D, McQuillan G, Johnson R, et al. Herpes simplex virus type 2 in the United States. 1976 to 1994. N Engl J Med. 1997;337:1105–11.
Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190:1374–81.
Johnson LS, Nahmias AJ, Magder RE, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989;321:7–12.
Lafferty WE, Downey L, Celum C, Wals A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis. 2000;181:1454–7.
Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir. In: Programms and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy; 1995. San Francisco, California; 1995.
Mertz GJ. Epidemiology of genital herpes infections. Infect Dis Clin North Am. 1993;7:825–39.
Mitchell PS, Espy MJ, Smith TF, Toal DR, Rys PN, Berbari EF, Osmon DR, Persing DH. Laboratory diagnosis of central nervous system infections with herpes simples virus by PCR performed with cerebrospinal fluid specimens. J Clin Microbiol. 1997;35:2873–7.
Patel R, Kennedy OJ, Clarke E, et al. European guidelines for the management of genital herpes. Int J STD AIDS. 2017;28(14):1366–79.
Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother. 1993;4:47–55.
Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006;42:418–27.
Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes. N Engl J Med. 1981;305:315–9.
Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA. 1996;276:44–9.
Safarin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med. 1991;325:551–5.
Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 2002;186:1718–25.
Shukla D, Spear PG. Herpesviruses and heapransulfate: an intimate relationship in aid of viral entry. J Clin Invest. 2001;108:503–10.
Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305:1441–9.
Wald A, Zeh J, Selke S, et al. Virologic characterisitcs of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770–5.
Wald A, Matson P, Ryncarz A, Corey L. Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. 1999. Sex Transm Dis. 1999;26:1–3.
Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, et al. Helicase –primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370:201–10.
Wals A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006;33:529–33.
Whitley RJ, Prichard M. A novel potential therapy for HSV. N Engl J Med. 2014;370:273–4.
Wildy P. Herpes history and classification. In: Kaplan AS, editor. The herpes viruses. New York: Academic; 1973. p. 1–25.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):27–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stary, A. (2023). Herpes Genitalis. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D'Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Cham. https://doi.org/10.1007/978-3-031-15130-9_37
Download citation
DOI: https://doi.org/10.1007/978-3-031-15130-9_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-15129-3
Online ISBN: 978-3-031-15130-9
eBook Packages: MedicineMedicine (R0)